← Back to Home

Eliciting an Immune Response in Colorectal Cancer “Cold Tumors”: Early STC-1010 Trial Opens Possibility of Surgery

In a nine-patient combination therapy trial, three patients with initially unresectable tumors became eligible for surgery, and two had no evidence of disease after surgery. This is a preliminary signal; controlled studies are still needed to clarify how much additional benefit the new therapy provides.

By SURL BioNews

For patients with metastatic colorectal cancer whose tumors are initially unresectable, treatment that makes surgery possible could change the subsequent course of care. Brenus Pharma announced on October 23 that, in an early trial of the experimental immunotherapy STC-1010 combined with first-line chemotherapy, three of seven evaluable patients became eligible for surgery, with two showing no evidence of disease after surgery. However, these results come from a small combination therapy study, and the contribution of the new drug itself cannot yet be determined.

The study targets mismatch repair-proficient, microsatellite-stable (pMMR/MSS) colorectal cancer. These tumors typically have difficulty eliciting an effective antitumor immune response and are therefore called “cold tumors.” According to the company, STC-1010 is designed to make tumors easier for the immune system to recognize and to initiate subsequent immune responses through antigen presentation involving dendritic cells.

The reported results are from the Phase Ia dose-escalation stage of the BreAK CRC-001 trial, in which nine patients received treatment, with a median follow-up of eight months. The proportions of patients with liver metastases and KRAS mutations were each 89%. In addition to STC-1010 and chemotherapy, the regimen included low-dose cyclophosphamide, with GM-CSF used in some cases. The observed changes should therefore be viewed as results of the full combination regimen.

Regarding safety, the company reported no dose-limiting toxicities, and all treatment-related adverse events were Grade 1 or 2. Under RECIST 1.1 criteria, four of seven evaluable patients achieved an objective response, for a response rate of 57%; all seven achieved disease control. These figures provide a basis for further research, but the denominator is very small, and a single patient’s outcome would substantially change the percentages.

The three patients who became eligible for surgery accounted for approximately 43% of evaluable patients. The announcement’s headline described the results as “two complete responses,” while the body explicitly stated that the two patients had no evidence of disease after surgery; these two descriptions cannot be treated directly as the same measure of drug efficacy. The available data are also insufficient to infer that the cancer has been cured or how long this status might last.

Immune analyses added another layer of clues to the clinical results. Data from the first six patients showed a 285% increase from baseline in intratumoral CD8-positive T-cell infiltration, while the ratio of CD4-positive T cells to regulatory T cells rose to 2.5 times its baseline level. These changes are consistent with the study’s aim of enhancing immune recognition of tumors, but they are still insufficient to prove that the immune changes caused tumor shrinkage or can predict long-term survival.

The Business Wire release carried by ANSA identified the presentation as poster 1023P at ESMO 2026; both it and the content carried by STT Info came from the company’s press release and do not constitute two independent verifications. The study currently lacks a control group, and the announcement did not explain why the other two patients were excluded from the efficacy evaluation. More complete trial data, longer follow-up, and controlled studies are needed to determine whether STC-1010 truly increases opportunities for surgery and durable disease control beyond chemotherapy alone.

References

  1. BioSpace
  2. Business Wire via STT Info
  3. ANSA / Business Wire